摘要
Ⅰa类抗心律失常药(西苯唑啉)被用于治疗室上性和室性心律失常。然而研究发现,苯唑啉还能显著降低肥厚型梗阻性心肌病梗阻部位的压差,提高肥厚心肌的舒张功能,改善患者的临床症状,长期使用安全、方便且效果稳定。本文总结临床上用其治疗各种类型肥厚型心肌病的实践经验,阐述西苯唑啉在心血管疾病方面的新应用,为肥厚型心肌病的患者提供新而有效的治疗方法,并探讨西苯唑啉治疗肥厚型心肌病的可能机制。
Class I antiarrhythmic drug cibenzoline once was used for su-praventricular or ventricular arrhythmias.However cibenzoline was found to decrease the pressure gradient significantly , at the same time improve the diastolic function and clinical symptoms of the obstructive hypertro-phic cardiomyopathy（HCM） safely, conveniently,stably in a long peri-od.This review was to investigate the mechanisms of treating HCM ,sum-marize the experience and explain the new application of cibenzoline.As a result , offering aneffective choice and reducing the adverse effect as well as promoting the quality of life of HCM patients.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第7期647-649,656,共4页
The Chinese Journal of Clinical Pharmacology
基金
国家重大新药创制科技重大专项基金资助项目(2012ZX09303-008-001)
国家临床重点专科建设--《卫生部重点实验室项目》基金资助项目
关键词
西苯唑啉
梗阻
压差
肥厚型心肌病
心律失常
cibenzoline
obstruction
pressure gradient
hypertrophic cardiomyopathy
arrhythmias
